Abstract: A method for identifying mild cognitive impairment by at least one processor of an apparatus according to some embodiments of the present disclosure is disclosed. the method comprises performing a task of acquiring digital biomarker data for identifying mild cognitive impairment of a user of a user terminal; performing a preliminary task to allow the user to check the task before performing the task; and acquiring gaze information of the user in conjunction with performing the task and the preliminary task; wherein the gaze information is used when determining displayed information in the preliminary task, and used when identifying mild cognitive impairment of the user in the task.

Abstract: Disclosed is a method of identifying, by at least one processor of a device, a cognitive function state of a user. The method may include inputting user information, at least one voice data, and speech time information related to the at least one voice data to a cognitive function state identification model, and identifying a cognitive function state of the user based on first output data that is output by the cognitive function state identification model.

Abstract: Disclosed is a method of identifying, by at least one processor of a device, a cognitive function state of a user. The method may include inputting user information, at least one voice data, and speech time information related to the at least one voice data to a cognitive function state identification model, and identifying a cognitive function state of the user based on first output data that is output by the cognitive function state identification model.

Abstract: Disclosed is a method of identifying dementia by at least one processor of a device. The method may include obtaining content analysis information and voice activity analysis information by using a plurality of first voice data and second voice data which have been obtained by performing a plurality of tasks in a user terminal, and identifying dementia by inputting the content analysis information and the voice activity analysis information to a dementia identification model.

Abstract: The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with ?-galactosylceramide (?GalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

Abstract: The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with ?-galactosylceramide (?GalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.